KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Shares Outstanding (Diluted Average) (2016 - 2025)

Arbutus Biopharma's Shares Outstanding (Diluted Average) history spans 16 years, with the latest figure at $191.6 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 3.23% to $191.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $191.6 million, a 3.23% increase, with the full-year FY2025 number at $191.6 million, up 3.23% from a year prior.
  • Shares Outstanding (Diluted Average) hit $191.6 million in Q4 2025 for Arbutus Biopharma, roughly flat from $191.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for ABUS hit a ceiling of $191.6 million in Q4 2025 and a floor of $93.4 million in Q1 2021.
  • Historically, Shares Outstanding (Diluted Average) has averaged $157.9 million across 5 years, with a median of $166.0 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): surged 58.86% in 2022 and later rose 1.24% in 2025.
  • Tracing ABUS's Shares Outstanding (Diluted Average) over 5 years: stood at $106.2 million in 2021, then skyrocketed by 42.07% to $150.9 million in 2022, then rose by 9.95% to $166.0 million in 2023, then grew by 11.84% to $185.6 million in 2024, then increased by 3.23% to $191.6 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for ABUS at $191.6 million in Q4 2025, $191.3 million in Q3 2025, and $191.1 million in Q2 2025.